北陆药业所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：医药电商、干细胞、基 因测序、原料药、中药等。 北陆药业今年以来股价涨41.46%，近5个交易日跌1.02%，近20日跌0.91%，近60日跌16.98%。 今年以来北陆药业已经2次登上龙虎榜，最近一次登上龙虎榜为6月17日，当日龙虎榜净买入3375.52万 元；买入总计9540.19万元 ，占总成交额比11.17%；卖出总计6164.67万元 ，占总成交额比7.22%。 资料显示，北京北陆药业股份有限公司位于北京市海淀区西直门北大街32号枫蓝国际写字楼A座7层， 成立日期1992年9月5日，上市日期2009年10月30日，公司主营业务涉及对比剂系列、中枢神经类和降糖 类药品的生产、研发与销售。主营业务收入构成为：对比剂63.33%，中成药22.09%，降糖药12.75%， 其他(补充)1.83%。 11月18日，北陆药业盘中下跌2.03%，截至14:27，报8.70元/股，成交1.15亿元，换手率2.33%，总市值 48.97亿元。 资金流向方面，主力资金净流出1513.50万元，特大单买入0.00元，占比0.00%，卖出235.48万 ...

法律意见书 北京市中伦律师事务所 关于北京北陆药业股份有限公司 2025 年第四次临时股东会的 法律意见书 致：北京北陆药业股份有限公司 北京市中伦律师事务所（以下简称"本所"）作为北京北陆药业股份有限公司 （以下简称"公司"）的常年法律顾问，受公司委托，指派律师出席公司2025年第 四次临时股东会（以下简称"本次股东会"）。本所律师根据《中华人民共和国公 司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证 券法》"）《上市公司股东会规则》等相关法律、法规、规范性文件及《北京北 陆药业股份有限公司章程》（以下简称"《公司章程》"）的规定，对本次股东会 进行见证并出具法律意见。 本所及经办律师依据《证券法》《律师事务所从事证券法律业务管理办法》 和《律师事务所证券法律业务执业规则》等规定及本法律意见书出具日以前已经 发生或者存在的事实，严格履行了法定职责，遵循了勤勉尽责和诚实信用原则， 进行了充分的核查验证，保证本法律意见所认定的事实真实、准确、完整，所发 表的结论性意见合法、准确，不存在虚假记载、误导性陈述或者重大遗漏，并承 担相应法律责任。 为出具本法律意见书，本所律师独立、客观、公 ...

股票代码：300016 股票简称：北陆药业 公告编号：2025-118 北京北陆药业股份有限公司 2025年第四次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会无增加、变更、否决提案的情况； 2、本次股东会未涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 1、会议召开的日期和时间： （1）现场会议召开时间为：2025年11月13日（星期四）下午14：30 （2）网络投票时间为：通过深圳证券交易所交易系统进行网络投票的具 体时间为2025年11月13日9：15—9：25、9：30—11：30、13：00—15：00； 通过深圳证券交易所互联网投票系统投票的时间为2025年11月13日上午9：15 至下午15：00期间的任意时间。 2、召开地点：北京市海淀区西直门北大街 32 号枫蓝国际写字楼 A 座 7 层 A1 会议室 6、会议召开的合法、合规性：公司第九届董事会第五次会议审议通过了 《关于召开 2025 年第四次临时股东会的议案》，本次股东会会议的召开符合 有关法律、行政法规、部门规章、规范性文件和《 ...

Core Viewpoint - Beilu Pharmaceutical (300016.SZ) has developed a proprietary traditional Chinese medicine, Jiuwei Zhenxin Granules, which is approved by the National Medical Products Administration for the treatment of generalized anxiety disorder and is included in the medical insurance catalog, making it an exclusive product of the company [1] Group 1 - Jiuwei Zhenxin Granules is a self-developed innovative traditional Chinese medicine by the company [1] - The product is a pure traditional Chinese medicine formulation approved for treating generalized anxiety disorder [1] - It is also a medical insurance product, indicating its significance in the healthcare market [1]

Core Viewpoint - Beilu Pharmaceutical (300016.SZ) has developed a proprietary traditional Chinese medicine, Jiuwei Zhenxin Granules, which has been approved by the National Medical Products Administration for the treatment of generalized anxiety disorder and is included in the medical insurance catalog, making it a unique product of the company [1] Group 1 - Jiuwei Zhenxin Granules is a self-developed innovative traditional Chinese medicine by the company [1] - The product is a pure traditional Chinese medicine formulation approved for treating generalized anxiety disorder [1] - It is also a medical insurance product, indicating its significance in the healthcare market [1]

股票代码：300016 股票简称：北陆药业 公告编号：2025-117 北京北陆药业股份有限公司 1 关于召开2025年第四次临时股东会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 北京北陆药业股份有限公司（以下简称"公司"）于2025年10月29日在 巨潮资讯网发布了《关于召开2025年第四次临时股东会的通知》，为进一步 保护投资者的合法权益，方便公司股东行使股东会表决权，现将股东会的有 关事项提示如下： 一、召开会议的基本情况 1、股东会届次：2025年第四次临时股东会 2、股东会的召集人：董事会 3、会议召开的合法、合规性：公司第九届董事会第五次会议审议通过了 《关于召开2025年第四次临时股东会的议案》，本次股东会会议的召开符合有 关法律、行政法规、部门规章、规范性文件和《公司章程》等规定。 4、会议时间： （1）现场会议时间：2025年11月13日14:30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间 为2025年11月13日9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所 互 ...

Group 1 - The core viewpoint of the news is that Beilu Pharmaceutical has shown a significant increase in stock price and positive financial performance indicators, indicating potential growth and investor interest [1][2]. Group 2 - As of November 12, Beilu Pharmaceutical's stock price increased by 2.05% to 8.97 CNY per share, with a total market capitalization of 5.049 billion CNY [1]. - The company has experienced a year-to-date stock price increase of 45.85%, with a recent 5-day increase of 2.99% and a 20-day increase of 2.28%, although it has seen a decline of 8.38% over the past 60 days [1]. - Beilu Pharmaceutical's main business segments include contrast agents (63.33% of revenue), traditional Chinese medicine (22.09%), and diabetes medications (12.75%) [1]. Group 3 - For the period from January to September 2025, Beilu Pharmaceutical achieved operating revenue of 873 million CNY, representing a year-on-year growth of 19.59%, and a net profit attributable to shareholders of 44.177 million CNY, reflecting an 81.10% increase [2]. - The company has distributed a total of 369 million CNY in dividends since its A-share listing, with 59.03 million CNY distributed over the past three years [3].

Group 1 - Digital Zhengtong's subsidiary Baoding Jindi won a bid for a smart water project in Jinan, with a total contract value of 109 million yuan, of which Baoding Jindi's share is approximately 77 million yuan [1] - Lingzhi Software plans to acquire 100% equity of Kaimiride through a combination of cash and stock issuance, with the final transaction price yet to be determined [1] - Tianjin Port's subsidiary plans to transfer 60% equity of China Railway Storage and Transportation, with an estimated value of 37.54 million yuan for the entire equity [2] Group 2 - New Wufeng reported a 56.97% year-on-year increase in pig sales in October, selling 610,000 pigs [3] - New Peng Co. announced a joint investment of approximately 15 million USD with Jabil to build a battery storage box project in Thailand [4] - Maiwei Bio received approval for a clinical trial of its 9MW3811 injection for pathological scars [6] Group 3 - Jiangsu Sopo completed maintenance and resumed production of its methanol and acetic acid facilities [8] - Luoniushan reported a 24.65% year-on-year increase in pig sales revenue in October, totaling 116 million yuan [9][10] - Zhongbei Communication signed a 1 billion yuan comprehensive computing service framework agreement with Xiamen Hongxin Electronics [11] Group 4 - Huayang New Materials announced the resignation of its general manager, Wu Yuehua [12] - Zhongxin Co. used 50 million yuan of idle funds to purchase structured deposits with expected annual returns between 0.55% and 2.05% [14] - Huajian Group's subsidiary signed a construction engineering design contract worth 96.54 million yuan [16] Group 5 - Jianyou Co. received FDA approval for a new production site for its injectable drug [17] - Beilu Pharmaceutical obtained a drug registration certificate for its iodine mepivacaine injection, which is included in the national medical insurance catalog [19] - *ST Yuancheng's stock will be suspended due to falling below the market cap threshold for delisting [20] Group 6 - Xiantan Co. reported a 9.3% year-on-year increase in chicken product sales revenue in October, totaling 503 million yuan [21] - Huanxu Electronics reported an 8.93% year-on-year decrease in consolidated revenue for October, amounting to 5.598 billion yuan [23] - Yisheng Co. reported a 22.97% year-on-year decrease in white feather chicken seed sales revenue in October [25] Group 7 - Yuandong Bio initiated a Phase I/II clinical trial for its ADC drug YLSH003 targeting advanced solid tumors [25] - Xiaoming Co. reported a 34.89% year-on-year decrease in chicken product sales revenue in October [26] - Nanjiao Food reported a 5.27% year-on-year decrease in consolidated revenue for October, totaling 235 million yuan [28] Group 8 - Chuangye Huikang announced a potential change in control, leading to a temporary stock suspension [30] - Tangrenshen reported a 17.91% year-on-year decrease in pig sales revenue in October, totaling 828 million yuan [32][33] - Wancheng Group plans to distribute a cash dividend of 1.5 yuan per 10 shares to shareholders [34] Group 9 - Kangguan Technology plans to distribute a cash dividend of 3.6 yuan per 10 shares to shareholders [36] - Shoudu Online's executive plans to reduce holdings of up to 19,400 shares [38] - Maolai Optical received approval for the issuance of convertible bonds [40] Group 10 - Jinkai New Energy plans to distribute a cash dividend of 0.1 yuan per share to shareholders [41] - Tianchen Medical raised the upper limit for share repurchase to 70 yuan per share [42] - Tianmu Lake used 38 million yuan of idle funds to purchase structured deposits [43]

Core Points - Beilu Pharmaceutical announced the convening of the 9th Board of Directors' fourth meeting on September 25, 2025, and the third extraordinary shareholders' meeting on October 14, 2025, to review the proposal for changing registered capital and amendments [1] - The "Beilu Convertible Bonds" began conversion on June 11, 2021, and triggered conditional redemption on July 14, 2025 [1] - The company decided to redeem all "Beilu Convertible Bonds" at face value plus accrued interest, with trading ceasing on July 31, 2025, and conversion stopping on August 5, 2025 [1] - A total of 71,017,267 shares of "Beilu Pharmaceutical" were converted from the bonds, increasing the total share capital from 491,855,896 shares to 562,873,163 shares [1] - The registered capital changed from 491,855,896 yuan to 562,873,163 yuan, and the company completed the business registration change procedures [1]

Core Viewpoint - Beilu Pharmaceutical has received approval from the National Medical Products Administration for the registration certificate of Iodinated Contrast Agent Injection [2] Company Summary - Beilu Pharmaceutical announced the receipt of the drug registration certificate for Iodinated Contrast Agent Injection on November 10 [2]